MTS Health Partners: more information on firm?
Any opinions on this firm?
Any opinions on this firm?
+523 | BofA Associate death? | 20 | 1h | |
+149 | Investment Banking US League Table YTD 2024 (FactSet) | 84 | 2h | |
+143 | Big Layoff at Barclays - 5/1/24 | 76 | 1h | |
+87 | “Americans just work harder” | 53 | 15h | |
+83 | Would comitting to ATL İB be stupid? Please give feedback. | 45 | 2d | |
+68 | Sleeping on Jefferies??? | 32 | 13h | |
+66 | A shitter's comprehensive guide to sophomore year recruiting | 7 | 13h | |
+59 | NEED NY RESTAURANT RECOMMENDATIONS | 38 | 2d | |
+57 | What's up with RBC nowadays? | 24 | 9h | |
+50 | 5-Step (Borderline Psycho) Pre-Superday Routine I Used to Land Every IB Internship Offer | 4 | 2d |
Career Resources
bump. they just posted a job for an analyst
mts health partners rep (Originally Posted: 09/23/2013)
.
Analyst or Assoc?
Analyst program
i interviewed in july for an immediate position. Asked a lot about biotech specific dcf, other than that it was pretty standard. know your previous banking experience
They use headhunters last time I heard - off cycle hiring of course.
.
anybody know anything about these guys?
I interviewed there about a year ago for FT. Pretty standard banking questions, maybe a little more geared to biotech as mentioned above. Started by a former Bear guy and seemed like a bit of a sweatshop with just ok deal flow. They have a VC/PE arm, but I don't think there's much interaction between them and their IBD (could be completely off-base on that one). Can't speak much to their rep. Overall, I didn't really like the impression they gave off and would not like to work there, but that's just one (fairly uninformed) opinion.
in 2017, would second all of the above with the caveat that there is zero interaction between IBD and PE. More a biotech play than corpfin, don't be misled by the announcements...
thanks bro
Bump! Any updates on comp/exit opps/ability to lateral?
Comp is street. Exit opp's are a mix of PE, HF and corporate. All healthcare-focused, with very few exceptions (think Frazier, Waud, Healthcare Royalty Partners, etc. etc.) Well-respected enough in their spaces that you can lateral into other healthcare banking groups.
Think strongly about if you are ready to commit to healthcare before joining
Any updated information on MTS?
Know a couple of the current analysts there. Most of the people are pretty nice. I think the firm has a total of 30-40ish people. The work that they do is obviously entirely life science focused and clients tend to be on the smaller side. In terms of exit opps, I have heard an analyst say "if your goal is to go to a MF don't come here". People who go to MTS genuinely love science and exits tend to be towards Corp Finance/VC/lateral to other banks.
Have intimate knowledge of the firm for a variety of reasons. Bottom line: well-respected healthcare (primarily M&A) advisory shop. If you are genuinely interested in healthcare, this firm is a good place to be. If not, probably not for you. Firm is 70/80 individuals, with the majority in New York, with a handful in San Francisco and Tokyo. The firm is focused on two core businesses: (1) life sciences advisory, and (2) healthcare services advisory. MTS is no longer affiliated with its (former) private equity affiliate, WindRose Health Investors.
The life sciences group provides sell- and buy-side M&A, royalty monetizations (and other structured finance products), reverse mergers, and equity financing (think private placements). The coverage universe for this group includes any and all biopharmaceutical companies (i.e., early stage, pre-revenue biotech, to multi-hundred billion dollar pharma). Currently, this group is definitely more active than the services business. Very intensive coverage model (read: pitch books with profiles), which has generated significant deal flow across the product lines. Strong class of partners, with some up-and-coming VP's/directors.
The healthcare services business provides sell- and buy-side M&A, restructurings, recapitalizations and general capital structure advisory. Coverage universe is largely publicly-traded and sponsor-owned provider/payor/outsourced services/facilities business. Also have an up-and-coming HCIT business. Sell-side business is not as strong as comparables (I think of Jefferies and the Blair's/HW's of the world), but they are upmarket with respect to the clients and deals they are around (albeit, can be a bit confined to their spaces of expertise). Have some very respectable clients. Again, the partner/MD class is strong.
The profile of analyst/associate is heavily skewed towards people who are demonstrably interested in healthcare (think people coming from UPenn's Vagelos program, people with healthcare/pharma/medicine academic/work experience backgrounds, etc.). Primarily recruit out of Penn, Cornell, Columbia and a handful of other schools. Analysts/associates typically begin to specialize or migrate to one group or another after a year or so. Which group will heavily influence exit opp's and experience. As mentioned above, the life sciences group is very "science-y", while the services group is pure-play corporate finance/sponsor coverage. Both groups heavy on M&A, however. As a result of the aforementioned experience biases, life sciences exits are typically to corporate development roles at biopharma companies. Have also been several exits in recent years to royalty principal investment shops (i.e., Healthcare Royalty Partners) and hedge funds (Citadel, Point72). The services exits are primarily private equity (as mentioned above, they are well represented at the respectable mid-market healthcare PE funds). No exits to mega-funds that come to mind. There have also been several exits to competing investment banks in recent years. They promote A-to-A and A-to-VP, as well.
.
Great write up and info. Sending a PM and a banana your way.
They sent someone to Bain Cap life sciences I believe
Bump. Does anyone have more info on interview process? How to best prepare?
Id voluptate illum molestias tempore consequatur voluptatum consequatur ipsa. Aut sunt eius saepe enim. Nesciunt aliquam ut voluptas nobis porro velit. Voluptas iste unde accusantium.
Eum non soluta omnis dolor laudantium. Vel dolorem at enim recusandae. Magnam cum eum eaque magnam totam. Est voluptatum exercitationem odit pariatur facere in illo et. Odit suscipit consequatur rem ut et ut. Similique praesentium voluptatibus iste voluptatum id aut. Dolorum distinctio suscipit perferendis ut.
Laborum mollitia aut assumenda in reprehenderit magni cupiditate eveniet. Eligendi provident explicabo ipsam autem non.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Tenetur suscipit optio voluptate molestias voluptas sed. Ullam assumenda eos non quas sed maxime. Quia dolor dolor modi nesciunt illo magnam. Voluptates odio soluta fugit eaque eligendi ea. Ea iste et aperiam voluptas.
Earum architecto in ullam provident. Sint excepturi natus temporibus quam. Alias maiores voluptate dolorum velit. Sed ut qui a expedita ratione.
Unde tempore similique omnis qui. Suscipit mollitia ipsam voluptas nemo quis minima eveniet. Est et iusto sit. Sequi fugiat fuga nesciunt nobis autem. Soluta sit id ea incidunt aut qui officiis. Adipisci dolor sed velit. Consequatur qui consequatur ut vel.